no statement of use filed
on 28 Jun 2021
Last Applicant/ Owned by
87 Cambridge Park Drive
Cambridge
MA
02140
Serial Number
88918443 filed on 15th May 2020
Registration Number
N/A
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
"ZILUCOPLAN"
The mark consists of the word "ZILUCOPLAN" in gray under the word "ZILBRYSQ", where the letters "ZILBRYS" of "ZILBRYSQ" are in a blue font and letter "Q" fades from orange to red to blue in a clockwise direction starting from the bottom of the "Q" and ending at the tail of the "Q". The wording "ZILBRYSQ ZILUCOPLAN" has no meaning in a foreign language. Pharmaceutical preparations, for human use,Read More
Pharmaceutical preparations, for human use, for the prevention and treatment of paroxysmal nocturnal hemoglobinuria, myasthenia gravis, an inflammatory disorder, a wound, a burn, an autoimmune disorder, a pulmonary disorder, a cardiovascular disorder, a neurological disorder, a kidney-related disorder, a diabetes-related disorder, an ocular disorder, and a pregnancy-related disorder; Pharmaceutical preparations, for human use, for the prevention and treatment of disorders of metabolism, the nervous system, the immune system, the cardio-vascular system, the respiratory system, the musculo-skeletal system, and the genitourinary system; Pharmaceutical preparations for the treatment of fibrotic and inflammatory disorders; Pharmaceutical preparations for use in dermatology, nephrology, hepatology, rheumatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations as anti-viral, anti-bacterial, or anti-fungal agents, all of the foregoing containing Zilucoplan
Syringes for injections; Syringes for medical purposes; Syringes for medical purposes sold empty which may be filled with pharmaceutical preparations, for human use, for the prevention and treatment of paroxysmal nocturnal hemoglobinuria, myasthenia gravis, an inflammatory indication, a wound, a burn, an autoimmune indication, a pulmonary indication, a cardiovascular indication, a neurological indication, a kidney-related indication, a diabetes-related indication, an ocular indication, and a pregnancy-related indication
No 88918443
No Service/Collective Mark
No 2011.2004TM
No
No
No
No
No
No
No
No
The mark consists of the word "ZILUCOPLAN" in gray under the word "ZILBRYSQ", where the letters "ZILBRYS" of "ZILBRYSQ" are in a blue font and letter "Q" fades from orange to red to blue in a clockwise direction starting from the bottom of the "Q" and ending at the tail of the "Q".
| Status Date | Action Taken |
|---|---|
| 28th Jun 2021 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
| 28th Jun 2021 | ABANDONMENT - NO USE STATEMENT FILED |
| 24th Nov 2020 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| 29th Sep 2020 | PUBLISHED FOR OPPOSITION |
| 29th Sep 2020 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| 09th Sep 2020 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| 08th Sep 2020 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| 01st Sep 2020 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| 01st Sep 2020 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| 01st Sep 2020 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
